Search
Spruce Biosciences Inc
SPRBAdd to Watchlist
52.510USD
-0.035-0.07%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
72.06MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Spruce Biosciences Inc is 8.80, ranking 53 out of 387 in the Biotechnology & Medical Research industry. The average price target is 209.50, with a high of 259.00 and a low of 160.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
149.714
Target Price
+167.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Spruce Biosciences Inc
SPRB
7
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Spruce Biosciences Inc's price target?
Analysts forecast that Spruce Biosciences Inc's price target is USD 209.50, with the highest forecast at USD 259.00 and the lowest forecast at USD 160.00.
How have Spruce Biosciences IncSPRB's recent earnings per share performed?
The market expectation was USD -8.94, while Spruce Biosciences IncSPRB's earnings per share (EPS) for the previous quarter was USD -11.28. EPS for the next quarter is expected at USD -6.11.
What is the analyst rating for Spruce Biosciences Inc?
Based on the ratings of Spruce Biosciences Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.